Clinical Trial Update: Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of GV1001 in healthy subjects; the trial, aimed at neurodegenerative disease application…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurodegenerative Disease

Drugs mentioned

• GV1001

Snippet

Sponsor: GemVax & Kael | Conditions: Neuro-Degenerative Disease | Phase 1 | Status: COMPLETED